Inhaled Tranexamic Acid As a Novel Treatment for Pulmonary Hemorrhage in Critically Ill Pediatric Patients: An Observational Study

Erika R O'Neil; Lindsay R Schmees; Karla Resendiz; Henri Justino; Marc M Anders

doi:10.1097/CCE.0000000000000075

Inhaled Tranexamic Acid As a Novel Treatment for Pulmonary Hemorrhage in Critically Ill Pediatric Patients: An Observational Study

Crit Care Explor. 2020 Jan 29;2(1):e0075. doi: 10.1097/CCE.0000000000000075. eCollection 2020 Jan.

Authors

Erika R O'Neil¹, Lindsay R Schmees^{1

2}, Karla Resendiz^{1

2}, Henri Justino³, Marc M Anders¹

Affiliations

¹ Section of Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
² Section of Critical Care Medicine, Department of Pharmacy, Baylor College of Medicine, Houston, TX.
³ Section of Pediatric Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.

Abstract

Objectives: To describe the use of inhaled or endotracheally instilled tranexamic acid in critically ill pediatric patients for the treatment of pulmonary hemorrhage, which can be severe, life-threatening, and include potentially high-risk management procedures.

Design: Retrospective observational study from 2011-2018 with patients followed until hospital discharge.

Setting: Free-standing children's hospital with an annual ICU volume of more than 3,500 yearly admissions.

Patients: Pediatric patients, ages 0 to 18 years, admitted to an ICU and who received at least one dose of inhaled or endotracheally instilled tranexamic acid were included.

Interventions: Inhaled or endotracheally instilled tranexamic acid.

Measurements and main results: This study described the efficacy and adverse effects of patients who received inhaled or endotracheally instilled tranexamic acid. A total of 19 patients met inclusion criteria; median age was 72 months (11-187 mo), most patients were female (11, 58%), and almost half our patients (8, 42%) had congenital heart disease. Nine of 19 encounters (47%) had diffuse alveolar hemorrhage, four (21%) had pulmonary hemorrhage related to major aortopulmonary collateral arteries, two (11%) had mucosal airway bleeding, two (11%) were iatrogenic, one had a pulmonary embolism, and one patient did not have their etiology of pulmonary hemorrhage determined. Cessation of pulmonary hemorrhage was achieved in 18 of 19 patients (95%) with inhaled tranexamic acid with no major adverse events recorded.

Conclusions and relevance: We demonstrate that inhaled tranexamic acid may be safely used to treat pulmonary hemorrhage from varied etiologies in critically ill pediatric patients. Prospective studies are required in this vulnerable population to determine optimal dosing and delivery strategies, as well as to define any differential effect according to etiology.

Keywords: inhaled tranexamic acid; pediatric; pulmonary hemorrhage.